Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$4.80 USD

4.80
1,810

0.00 (0.00%)

Updated Jun 18, 2026 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 247)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation

by Zacks Equity Research

Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.

Zacks Equity Research

Henry Schein (HSIC) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends.

Zacks Equity Research

Veeva (VEEV) Beats on Q4 Earnings, Narrows '23 Revenue View

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both of its segments.

Zacks Equity Research

Masimo's (MASI) SedLine Receives FDA's Pediatric Indication

by Zacks Equity Research

The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.

Zacks Equity Research

Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.

Zacks Equity Research

OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.

Zacks Equity Research

Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.

Debanjana Dey headshot

Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up

by Debanjana Dey

Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.

Zacks Equity Research

AllScripts Healthcare (MDRX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

AllScripts (MDRX) delivered earnings and revenue surprises of 154.84% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.